Natera Shares Are Dropping, and So Are Its Margins

During the afternoon session, Natera moved 9.89%, compared to -0.028% for the S&P 500.

Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is now trading -26.63% away from its average analyst target price of $72.71 per share. The 13 analysts following the stock have set target prices ranging from $28.0 to $97.0, and on average give Natera a rating of buy.

Over the last year, NTRA shares have gone down by -24.56%, which represents a difference of -15.07% when compared to the S&P 500. The stock's 52 week high is $63.65 per share and its 52 week low is $26.1. With its gross margins declining an average -7.74% over the last four years, Natera may not have a strong enough business to reverse this trend.

Date Reported Revenue (k) Cost of Revenue (k) Gross Margin YoY Growth
2021-12-31 $617,025 $512,490 16.94% -5.36%
2020-12-31 $370,075 $303,827 17.9% -56.82%
2019-12-31 $306,023 $209,368 41.45% 11.85%
2018-12-31 $247,190 $315,297 37.06% 11.63%
2017-12-31 $210,939 $140,910 33.2% n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.